“We are expecting potential registrational interim data this year from ongoing pivotal studies in muscle invasive bladder cancer, which if successful and approved, would nearly triple the total addressable patients in the U.S.”

In context

“study this year in cancer caked ibuzatrelvir, our second-generation COVID-19 oral antiviral candidate, continues its Phase 3 study. Within I&I, we continue to progress a portfolio of medicines that include two potential first-in-class tri-specific antibodies currently in Phase 2. Now let's discuss our commercial strategy. 2024 was a strong year of commercial execution and we are pleased with our progress in improving performance of our newly launched products and gaining and maintaining market share for several of our core brands. I will start by highlighting the strength and impact of our oncology portfolio. Padcev plus pembrolizumab is an important growth driver as it has already become the #1 prescribed first-line treatment for locally advanced metastatic urothelial cancer in the U.S. We are expecting potential registrational interim data this year from ongoing pivotal studies in muscle invasive bladder cancer, which if successful and approved, would nearly triple the total addressable patients in the U.S. Braftovi/Mektovi achieved a 27% year-over-year worldwide operational growth and expanded its leadership position in multiple BRAF tumors, which are some of the hardest to treat cancer. Yesterday, we announced that BRAFTOVI in combination with cetuximab mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with metastatic colorectal cancer with BRAF V600E mutation. We are very excited with the robust improvement in PFS and OS and are looking forward to presenting this data in a scientific conference. Lorbrena, a treatment for adults with ALK-positive metastatic non-small cell lung cancer, achieved 37% worldwide year-over-year operational growth and is emerging as a potential standard of care in the firs”